Robert Moldwin
NPI: 1275503021
Total Payments
$61,305
2024 Payments
$1,825
Companies
12
Transactions
39
Medicare Patients
2,982
Medicare Billing
$400,135
Payment Breakdown by Category
Consulting$47,760 (77.9%)
Research$11,510 (18.8%)
Food & Beverage$1,388 (2.3%)
Travel$551.00 (0.9%)
Education$96.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $47,760 | 16 | 77.9% |
| Unspecified | $11,510 | 6 | 18.8% |
| Food and Beverage | $1,388 | 14 | 2.3% |
| Travel and Lodging | $551.00 | 2 | 0.9% |
| Education | $96.00 | 1 | 0.2% |
Payments by Type
General
$49,795
33 transactions
Research
$11,510
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $19,031 | 12 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $13,439 | 5 | $0 (2024) |
| Allergan, Inc. | $11,216 | 11 | $0 (2021) |
| Ipsen Innovation | $10,750 | 1 | $0 (2017) |
| Teva Pharmaceuticals USA, Inc. | $4,101 | 3 | $0 (2018) |
| Shionogi Inc | $2,100 | 1 | $0 (2021) |
| Axonics, Inc. | $145.35 | 1 | $0 (2023) |
| Medtronic USA, Inc. | $140.54 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $125.00 | 1 | $0 (2018) |
| Abbott Laboratories | $119.67 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,825 | 2 | IRONWOOD PHARMACEUTICALS, INC ($1,200) |
| 2023 | $6,364 | 9 | ABBVIE INC. ($3,146) |
| 2022 | $22,593 | 7 | ABBVIE INC. ($13,385) |
| 2021 | $5,125 | 4 | Shionogi Inc ($2,100) |
| 2020 | $9,660 | 5 | Allergan, Inc. ($9,660) |
| 2019 | $296.93 | 3 | Allergan Inc. ($156.39) |
| 2018 | $4,345 | 5 | Teva Pharmaceuticals USA, Inc. ($4,101) |
| 2017 | $11,095 | 4 | Ipsen Innovation ($10,750) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/29/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: UROLOGY | ||||||
| 02/09/2024 | IRONWOOD PHARMACEUTICALS, INC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 11/22/2023 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/22/2023 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $0.68 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/28/2023 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $3.83 | General |
| 09/18/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $1,250.00 | Research |
| Study: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) • Category: UROLOGY | ||||||
| 05/05/2023 | Ironwood Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 04/29/2023 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $73.00 | General |
| Category: GI | ||||||
| 03/22/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $937.50 | Research |
| Study: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) • Category: UROLOGY | ||||||
| 02/24/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $937.50 | Research |
| Study: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) • Category: UROLOGY | ||||||
| 02/15/2023 | Axonics, Inc. | Bulkamid (Device), Axonics | Food and Beverage | In-kind items and services | $145.35 | General |
| Category: Urology | ||||||
| 08/19/2022 | ABBVIE INC. | BOTOX (Biological) | — | Cash or cash equivalent | $2,760.00 | Research |
| Study: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) • Category: NEUROSCIENCE | ||||||
| 08/08/2022 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 07/22/2022 | ABBVIE INC. | BOTOX (Biological) | — | Cash or cash equivalent | $1,250.00 | Research |
| Study: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) • Category: NEUROSCIENCE | ||||||
| 05/26/2022 | ABBVIE INC. | BOTOX (Biological) | — | Cash or cash equivalent | $4,375.00 | Research |
| Study: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitisx2FBladder Pain Syndrome (ICx2FBPS) • Category: FACIAL AESTHETICS | ||||||
| 05/06/2022 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $42.00 | General |
| Category: Pain Management | ||||||
| 04/20/2022 | Ironwood Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $8,800.00 | General |
| 04/20/2022 | Ironwood Pharmaceuticals, Inc | — | Travel and Lodging | Cash or cash equivalent | $366.00 | General |
| 09/14/2021 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 06/14/2021 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 04/21/2021 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $460.00 | General |
| 03/08/2021 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| 09/11/2020 | Allergan, Inc. | BOTOX COSMETIC (Biological) | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| 09/11/2020 | Allergan, Inc. | BOTOX COSMETIC (Biological) | Consulting Fee | Cash or cash equivalent | $460.00 | General |
| 07/16/2020 | Allergan, Inc. | BOTOX COSMETIC (Biological) | Consulting Fee | Cash or cash equivalent | $3,680.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitisx2FBladder Pain Syndrome (ICx2FBPS) | ABBVIE INC. | $4,375 | 1 |
| Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | ABBVIE INC. | $4,010 | 2 |
| Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | AbbVie Inc. | $3,125 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 771 | 2,034 | $822,821 | $107,812 |
| 2022 | 12 | 702 | 1,285 | $795,873 | $95,928 |
| 2021 | 17 | 850 | 2,025 | $752,948 | $120,645 |
| 2020 | 10 | 659 | 1,651 | $555,923 | $75,750 |
Total Patients
2,982
Total Services
6,995
Medicare Billing
$400,135
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 185 | 263 | $181,207 | $28,694 | 15.8% |
| 64566 | Insertion of lower leg neurostimulator electrode | Office | 2023 | 27 | 177 | $127,971 | $19,981 | 15.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 92 | 115 | $112,585 | $18,439 | 16.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 107 | 155 | $76,570 | $12,245 | 16.0% |
| 51700 | Simple bladder irrigation and/or instillation | Facility | 2023 | 49 | 265 | $134,090 | $7,053 | 5.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $42,420 | $6,683 | 15.8% |
| 51700 | Simple bladder irrigation and/or instillation | Office | 2023 | 19 | 70 | $35,420 | $4,701 | 13.3% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 48 | 53 | $60,791 | $3,911 | 6.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $11,921 | $1,905 | 16.0% |
| 51728 | Complex measurement of pressure of urine flow in bladder with voiding pressure studies | Facility | 2023 | 13 | 13 | $7,160 | $1,241 | 17.3% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 89 | 99 | $11,088 | $993.24 | 9.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 19 | $5,947 | $960.66 | 16.2% |
| 51797 | Insertion of device into abdomen with pressure and urine flow rate study | Facility | 2023 | 13 | 13 | $5,390 | $480.87 | 8.9% |
| 51784 | Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | Facility | 2023 | 13 | 13 | $5,136 | $222.95 | 4.3% |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | Office | 2023 | 19 | 68 | $612.00 | $137.72 | 22.5% |
| J1644 | Injection, heparin sodium, per 1000 units | Office | 2023 | 17 | 650 | $650.00 | $112.79 | 17.4% |
| 51741 | Electronic assessment of bladder emptying | Facility | 2023 | 13 | 13 | $3,862 | $52.00 | 1.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 185 | 275 | $189,475 | $30,133 | 15.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 75 | 85 | $83,215 | $13,148 | 15.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 119 | 156 | $77,064 | $13,036 | 16.9% |
| 64566 | Insertion of lower leg neurostimulator electrode | Office | 2022 | 18 | 97 | $70,131 | $11,179 | 15.9% |
| 51700 | Simple bladder irrigation and/or instillation | Facility | 2022 | 58 | 320 | $161,920 | $9,170 | 5.7% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 76 | 87 | $99,789 | $6,515 | 6.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $36,360 | $5,822 | 16.0% |
| 51700 | Simple bladder irrigation and/or instillation | Office | 2022 | 12 | 44 | $22,264 | $2,868 | 12.9% |
About Robert Moldwin
Robert Moldwin is a Urogynecology and Reconstructive Pelvic Surgery healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275503021.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robert Moldwin has received a total of $61,305 in payments from pharmaceutical and medical device companies, with $1,825 received in 2024. These payments were reported across 39 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($47,760).
As a Medicare-enrolled provider, Moldwin has provided services to 2,982 Medicare beneficiaries, totaling 6,995 services with total Medicare billing of $400,135. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Urogynecology and Reconstructive Pelvic Surgery
- Other Specialties Urology
- Location New Hyde Park, NY
- Active Since 01/25/2006
- Last Updated 06/26/2024
- Taxonomy Code 2088F0040X
- Entity Type Individual
- NPI Number 1275503021
Products in Payments
- BOTOX (Biological) $17,135
- Dysport 300 U-1 (Drug) $10,750
- BOTOX COSMETIC (Biological) $9,781
- AJOVY (Drug) $4,101
- VENCLEXTA (Drug) $1,875
- Bulkamid (Device) $145.35
- INTERSTIM (Device) $140.54
- BOTOX OAB (Drug) $129.43
- XTANDI (Drug) $125.00
- BOTOX-UROLOGY (Drug) $120.04
- Axium INS DRG IPG (Device) $119.67
- Urolift - UL400 (Device) $96.00
- Linzess (Drug) $73.00
- Qutenza (Drug) $42.00
- BOTOX (Drug) $35.16
- LUPRON DEPOT (Drug) $16.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.